Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised studyCOLOZZA, M; BISAGNI, G; RONDINI, E et al.European journal of cancer (1990). 2002, Vol 38, Num 17, pp 2279-2288, issn 0959-8049, 10 p.Article

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry : correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumabGARI, S; SIDONI, A; DE ANGELIS, V et al.Annals of oncology. 2009, Vol 20, Num 4, pp 648-654, issn 0923-7534, 7 p.Article

Regional node failure in patients with four or more positive lymph nodes submitted to conservative surgery followed by radiotherapy to the breastARISTEI, C; MARSELLA, A. R; CHIONNE, F et al.American journal of clinical oncology. 2000, Vol 23, Num 3, pp 217-221, issn 0277-3732Article

Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracilCOLOZZA, M; TONATO, M; GRIGNANI, F et al.Cancer. 1988, Vol 62, Num 2, pp 262-265, issn 0008-543XArticle

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancerGORI, S; COLOZZA, M; CRINO, L et al.British journal of cancer. 2004, Vol 90, Num 1, pp 36-40, issn 0007-0920, 5 p.Article

Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patientsLUDOVINI, V; SIDONI, A; RODINO, C et al.Breast cancer research and treatment. 2003, Vol 81, Num 2, pp 159-168, issn 0167-6806, 10 p.Article

Salvage chemotherapy in metastatic breast cancer : An experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorinCOLOZZA, M; GORI, S; MOSCONI, A. M et al.Breast cancer research and treatment. 1996, Vol 38, Num 3, pp 277-282, issn 0167-6806Article

Long-term toxic effects of adjuvant chemotherapy in breast cancerAZIM, H. A; DE AZAMBUJA, E; COLOZZA, M et al.Annals of oncology. 2011, Vol 22, Num 9, pp 1939-1947, issn 0923-7534, 9 p.Article

Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12 155 patientsDE AZAMBUJA, E; CARDOSO, F; DE CASTRO JR, G et al.British journal of cancer. 2007, Vol 96, Num 10, pp 1504-1513, issn 0007-0920, 10 p.Article

Proliferative markers as prognostic and predictive tools in early breast cancer : where are we now?COLOZZA, M; AZAMBUJA, E; CARDOSO, F et al.Annals of oncology. 2005, Vol 16, Num 11, pp 1723-1739, issn 0923-7534, 17 p.Article

Chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) in patients with metastatic breast cancerCOLOZZA, M; GORI, S; TONATO, M et al.American journal of clinical oncology. 1989, Vol 12, Num 2, pp 137-141, issn 0277-3732Article

Pharmacokinetics of vincristine in cancer patients treated with nifedipineFEDELI, L; COLOZZA, M; DAVIS, S et al.Cancer. 1989, Vol 64, Num 9, pp 1805-1811, issn 0008-543X, 7 p.Conference Paper

Evaluation of serum HER2 extracellular domain in early breast cancer patients : correlation with clinicopathological parameters and survivalLUDOVINI, V; GORI, S; RULLI, A et al.Annals of oncology. 2008, Vol 19, Num 5, pp 883-890, issn 0923-7534, 8 p.Article

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancerAZAMBUJA, E; DURBECQ, V; ROSA, D. D et al.Annals of oncology. 2008, Vol 19, Num 2, pp 223-232, issn 0923-7534, 10 p.Article

Survival, quality of life and breast cancerMOSCONI, P; COLOZZA, M; DE LAURENTIIS, M et al.Annals of oncology. 2001, Vol 12, pp S15-S19, issn 0923-7534, SUP3Conference Paper

Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and CyclophosphamideCOLOZZA, M; MOSCONI, A. M; GORI, S et al.American journal of clinical oncology. 1997, Vol 20, Num 5, pp 522-526, issn 0277-3732Article

Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer : long-term resultsCOLOZZA, M; GORI, S; MOSCONI, A. M et al.American journal of clinical oncology. 1996, Vol 19, Num 1, pp 10-17, issn 0277-3732Article

5-fluorouracil and isoprinosine in the treatment of advanced colorectal cancer: a limited phase, I, II evaluationCOLOZZA, M; TONATO, M; BELSANTI, V et al.Cancer. 1988, Vol 62, Num 6, pp 1049-1052, issn 0008-543XArticle

CLASSIFICAZIONE IN STADI DELLA LEUCEMIA LINFATICA CRONICA E SUO SIGNIFICATO PROGNOSTICO = CLASSIFICATION EN STADE DE LA LEUCEMIE LYMPHOIDE CHRONIQUE ET SA SIGNIFICATION PRONOSTIQUEVELARDI A; SPINOZZI F; SIRACUSA A et al.1980; HAEMATOLOGICA; ITA; DA. 1980; VOL. 65; NO 1; PP. 82-95; ABS. ENG; BIBL. 18 REF.Article

Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung: a pilot studyDAVIS, S; TONATO, M; CRINO, L et al.Cancer. 1986, Vol 58, Num 5, pp 1018-1019, issn 0008-543XArticle

Expression of aphidicolin-induced fragile sites in lymphocytes of patients with breast cancerARDISIA, C; VENTI, G; COLOZZA, M. A et al.Cancer genetics and cytogenetics. 1993, Vol 67, Num 2, pp 113-116, issn 0165-4608Article

Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma : a prospective randomized trial of the Italian oncology group for clinical researchCOCCONI, G; BISAGNI, G; PASSALACQUA, R et al.Journal of clinical oncology. 1991, Vol 9, Num 4, pp 664-669, issn 0732-183XArticle